Aktuelle Zahlen aus der pharmazeutischen Industrie zeigen, dass die Entwicklung von neuen Produkten immer länger dauert und immer mehr kostet. Zudem schaffen immer weniger Produkte die Hürde der klinischen Entwicklung. Man spricht schon fast von einem Produktivitätsproblem der Forschung und...

This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of 74 countries. The identification strategy exploits the different timing across countries of two sets of IPR reforms. Domestic innovation is measured as citation-weighted...

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...